# Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

> **NCT04638582** · PHASE2 · TERMINATED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 6 (actual)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04638582
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-28
- **Primary completion:** 2026-04-14
- **Final completion:** 2026-04-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study was terminated due to low recruitment.
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638582, "Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04638582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*